On Thursday 07/11/2024 the closing price of the CVS Health Corp share was $59.05 on BTT.
Compared to the opening price on Thursday 07/11/2024 on BTT of $58.21, this is a gain of 1.42%.
CVS Health Corp's market capitalization is $74.10 B by 1.26 B shares outstanding.
Is CVS Health stock a Buy, Sell or Hold?
CVS Health stock has received a consensus rating of buy. The average rating score is and is based on 54 buy ratings, 13 hold ratings, and 0 sell ratings.What was the 52-week low for CVS Health stock?
The low in the last 52 weeks of CVS Health stock was 52.79. According to the current price, CVS Health is 111.67% away from the 52-week low.What was the 52-week high for CVS Health stock?
The high in the last 52 weeks of CVS Health stock was 83.25. According to the current price, CVS Health is 70.81% away from the 52-week high.What are analysts forecasts for CVS Health stock?
The 67 analysts offering price forecasts for CVS Health have a median target of 94.84, with a high estimate of 143.00 and a low estimate of 58.00. The median estimate represents a 62.16 difference from the last price of 58.95.CVS Health Stock Snapshot
59.04
Bid
109.00
Bid Size
59.06
Ask
148.00
Ask Size
7/12/2024
Date
4:34 PM
Time
419,240.00
Volume
59.05
Prev. Close
58.21
Open
1.26 B
Number of Shares
57.86
Day Low
59.56
Day High
58.95
52.79
52 Week Low
83.25
52 Week High
58.95
2.48
Dividend in USD
3.14
Dividend Yield
12.21
P/E Ratio
99.82
Free Float in %
6.49
EPS in USD
59.36
Book Value per Share in USD
10.41
Cash Flow per Share in USD
CVS Health News More News
Historical Prices for CVS Health
Date | Open | Close | Daily High | Daily Low |
---|
Price change over selected period:
0%
0
CVS Health Analyst Data
Total Analysts: 67
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price
*Price Target
Lowest: 58.00
Median: 94.84
Highest: 143.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.
CVS Health Analyst Opinions
- All
- Buy
- Hold
- Sell
Date | Analyst | Rating | Price | |||
---|---|---|---|---|---|---|
06/12/24 | Cantor Fitzgerald | Maintained Hold | $58 | |||
05/30/24 | J.P. Morgan | Maintained Buy | $86 | |||
05/30/24 | Baird Patrick & Co | Maintained Hold | $61 | |||
05/08/24 | Argus Research Company | Maintained Buy | $80 | |||
05/07/24 | Wells Fargo & Co | Maintained Hold | $60 | |||
05/02/24 | Bank of America Merrill Lynch | Maintained Buy | $77 | |||
05/02/24 | Goldman Sachs | Maintained Buy | $74 | |||
05/02/24 | Barclays Capital | Maintained Hold | $63 | |||
05/02/24 | UBS | Downgraded to Hold | $60 | |||
05/02/24 | Mizuho | Maintained Buy | $72 | |||
05/01/24 | Cantor Fitzgerald | Downgraded to Hold | $58 | |||
04/10/24 | Cantor Fitzgerald | Maintained Buy | $87 | |||
04/08/24 | Wells Fargo & Co | Maintained Hold | $76 | |||
04/04/24 | Cantor Fitzgerald | Maintained Buy | $87 | |||
03/15/24 | Piper Sandler | Maintained Buy | $94 | |||
03/06/24 | Barclays Capital | Maintained Hold | $78 | |||
02/08/24 | Cantor Fitzgerald | Maintained Buy | $87 | |||
02/08/24 | RBC Capital Markets | Maintained Buy | $84 | |||
12/22/23 | HSBC | Maintained Buy | $94 | |||
11/21/23 | Cantor Fitzgerald | Maintained Buy | $87 | |||
11/02/23 | RBC Capital Markets | Maintained Buy | $86 | |||
11/02/23 | Morgan Stanley | Maintained Buy | $100 | |||
09/19/23 | Evercore | Upgraded to Buy | $83 | |||
09/14/23 | Cantor Fitzgerald | Maintained Buy | $87 | |||
09/12/23 | Wolfe Research | Upgraded to Buy | $80 | |||
09/01/23 | Piper Sandler | Maintained Buy | $82 | |||
08/18/23 | RBC Capital Markets | Maintained Buy | $91 | |||
08/18/23 | Edward Jones | Downgraded to Hold | ||||
08/04/23 | Raymond James Financial, Inc. | Maintained Buy | $85 | |||
08/03/23 | Morgan Stanley | Maintained Buy | $110 | |||
08/03/23 | RBC Capital Markets | Maintained Buy | $91 | |||
08/03/23 | Barclays Capital | Maintained Buy | $86 | |||
07/12/23 | Barclays Capital | Maintained Buy | $89 | |||
07/11/23 | Mizuho | Maintained Buy | $88 | |||
07/07/23 | J.P. Morgan | Maintained Buy | $106 | |||
05/30/23 | J.P. Morgan | Maintained Buy | $114 | |||
05/26/23 | Piper Sandler | Maintained Buy | $85 | |||
05/09/23 | RBC Capital Markets | Maintained Buy | $102 | |||
05/08/23 | Wells Fargo & Co | Maintained Hold | $76 | |||
05/08/23 | Credit Suisse | Maintained Buy | $96 | |||
05/08/23 | Raymond James Financial, Inc. | Maintained Buy | $90 | |||
05/04/23 | Goldman Sachs | Maintained Buy | $88 | |||
05/04/23 | Barclays Capital | Maintained Buy | $90 | |||
05/02/23 | UBS | Maintained Buy | $94 | |||
05/02/23 | Bernstein | Maintained Hold | $93 | |||
04/21/23 | Cantor Fitzgerald | Maintained Buy | $87 | |||
03/31/23 | Bank of America Merrill Lynch | Maintained Buy | $104 | |||
03/30/23 | Barclays Capital | Maintained Buy | $100 | |||
02/09/23 | Jefferies & Company Inc. | Maintained Buy | $143 | |||
02/09/23 | RBC Capital Markets | Maintained Buy | $115 |
CVS Health Estimates* in USD
2024 | 2025 | 2026 | 2027 | 2028 | |
---|---|---|---|---|---|
Revenue | 368,734 | 386,777 | 408,881 | 433,611 | 450,443 |
Dividend | 2.53 | 2.61 | 2.92 | - | - |
Dividend Yield (in %) | 4.29 % | 4.42 % | 4.95 % | - | - |
EPS | 7.00 | 7.78 | 8.67 | 9.73 | 10.32 |
P/E Ratio | 8.43 | 7.58 | 6.80 | 6.06 | 5.71 |
EBIT | 14,933 | 15,489 | 16,564 | 17,251 | 18,580 |
EBITDA | 17,487 | 18,831 | 20,143 | 21,066 | - |
Net Profit | 7,843 | 8,774 | 9,643 | 10,343 | 10,717 |
Net Profit Adjusted | - | 9,724 | 10,720 | 11,373 | 12,319 |
Pre-Tax Profit | 11,208 | 12,400 | 13,555 | 14,641 | 16,590 |
Net Profit (Adjusted) | 8,826 | 9,779 | 12,859 | - | - |
EPS (Non-GAAP) ex. SOE | 7.00 | 7.78 | 8.67 | 9.73 | 10.32 |
EPS (GAAP) | 5.74 | 6.59 | 7.49 | 8.13 | 8.98 |
Gross Income | 54,337 | 58,304 | 61,967 | 66,772 | 71,364 |
Cash Flow from Investing | -8,099 | -8,957 | -7,933 | -7,635 | -6,314 |
Cash Flow from Operations | 11,777 | 12,996 | 14,280 | 15,355 | 17,018 |
Cash Flow from Financing | -8,099 | -8,957 | -7,933 | -7,635 | -6,314 |
Cash Flow per Share | 8.53 | 9.35 | 10.67 | - | - |
Free Cash Flow | 9,619 | 10,683 | 11,040 | 12,056 | 13,590 |
Free Cash Flow per Share | 7.62 | 7.58 | 7.94 | - | - |
Book Value per Share | 62.61 | 65.73 | 71.34 | - | - |
Net Debt | 53,245 | 49,756 | 44,708 | - | - |
Research & Development Exp. | - | - | - | - | - |
Capital Expenditure | 3,009 | 3,110 | 3,240 | 3,299 | 3,428 |
Selling, General & Admin. Exp. | 41,164 | 43,986 | 46,910 | - | - |
Shareholder’s Equity | 77,770 | 79,682 | 81,500 | 80,579 | 79,968 |
Total Assets | 251,197 | 252,937 | 259,145 | 269,410 | 275,784 |
Previous Quarter ending 06/30/24 |
Current Quarter ending 09/30/24 |
Next Quarter ending 12/31/24 |
Current Year ending 12/31/24 |
Next Year ending 12/31/25 |
|
---|---|---|---|---|---|
Earnings Estimates | |||||
No. of Analysts | 23 | - | - | 24 | 24 |
Average Estimate | 1.754 USD | - | - | 6.997 USD | 7.776 USD |
Year Ago | 1.482 USD | - | - | 6.493 USD | - |
Publish Date | 8/7/2024 | - | - | - | - |
Revenue Estimates | |||||
No. of Analysts | 18 | 18 | 18 | 25 | 23 |
Average Estimate | 91,375 USD | 92,236 USD | 96,345 USD | 368,734 USD | 386,777 USD |
Year Ago | 89,019 USD | 89,906 USD | 93,965 USD | 358,273 USD | - |
Publish Date | 8/7/2024 | 10/30/2024 | 2/5/2025 | - | - |
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet
Income Statements in Mio. USD
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|---|---|
Sales | 358,273.00 | 322,787.00 | 291,935.00 | 268,654.00 | 256,577.00 | 194,578.00 | 184,765.00 |
Change of sales in % | 10.99 | 10.57 | 8.67 | 4.71 | 31.86 | 5.31 | 4.08 |
Gross profit on sales | 54,928.00 | 54,614.00 | 51,872.00 | 48,994.00 | 45,329.00 | 31,537.00 | 28,547.00 |
Gross profit on sales change in % | 0.57 | 5.29 | 5.87 | 8.09 | 43.73 | 10.47 | -1.23 |
Operating income | 15,583.00 | 16,402.00 | 14,938.00 | 13,922.00 | 12,704.00 | 10,790.00 | 9,987.00 |
Operating income change in % | -4.99 | 9.80 | 7.30 | 9.59 | 17.74 | 8.04 | -6.06 |
Income before tax | 11,173.00 | 5,628.00 | 10,420.00 | 9,770.00 | 8,997.00 | 1,406.00 | 8,268.00 |
Income before tax change in % | 98.53 | -45.99 | 6.65 | 8.59 | 539.90 | -82.99 | -4.27 |
Income after tax | 8,344.00 | 4,149.00 | 7,910.00 | 7,179.00 | 6,629.00 | -597.00 | 6,598.00 |
Income after tax change in % | 101.11 | -47.55 | 10.18 | 8.30 | - | - | 24.73 |
Balance Sheet in Mio. USD
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|---|---|
Total liabilities | 181,094.00 | 164,950.00 | 165,115.00 | 168,788.00 | 160,124.00 | 139,667.00 | 57,436.00 |
Long-term liabilities per share | 79.12 | 73.24 | 73.61 | 81.50 | 82.04 | 73.87 | 26.42 |
Equity | 76,636.00 | 71,315.00 | 75,381.00 | 69,701.00 | 64,170.00 | 58,543.00 | 37,695.00 |
Equity change in % | 7.67 | -5.41 | 8.19 | 8.65 | 9.68 | 54.48 | 2.34 |
Balance sheet total | 257,730.00 | 236,265.00 | 240,496.00 | 238,489.00 | 224,294.00 | 198,210.00 | 95,131.00 |
Balance sheet total change in % | 9.09 | -1.76 | 0.84 | 6.33 | 13.16 | 108.35 | 0.71 |
Key Data in USD
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|---|---|
Sales per share | 277.73 | 243.98 | 219.67 | 204.46 | 196.61 | 186.38 | 180.43 |
P/E ratio (year end quote, basic EPS) | 12.21 | 29.72 | 17.33 | 12.50 | 14.62 | - | 11.26 |
P/E ratio (year end quote, diluted EPS) | 12.21 | 29.72 | 17.33 | 12.50 | 14.62 | - | 11.26 |
P/E ratio (year end quote) | 12.21 | 29.72 | 17.33 | 12.50 | 14.62 | - | 11.26 |
Dividend yield in % | 3.14 | 2.42 | 1.99 | 2.93 | 2.69 | 3.05 | 2.76 |
Equity ratio in % | 29.67 | 30.06 | 31.22 | 29.10 | 28.47 | 29.38 | 39.62 |
Debt ratio in % | 70.27 | 69.82 | 68.66 | 70.77 | 71.39 | 70.46 | 60.38 |
CVS Health Insider Activity
Name | Date | shares traded | shares held | Price | type (sell/buy) | option |
---|---|---|---|---|---|---|
AGUIRRE FERNANDO | 05/15/2024 | 2,347.00 | 34,523.00 | 57.52 | Buy | No |
BROWN C DAVID II | 05/15/2024 | 2,314.00 | 121,434.00 | 57.52 | Buy | No |
Balser Jeffrey R. | 05/15/2024 | 2,184.00 | 7,277.00 | 57.52 | Buy | No |
Mahoney Michael F | 05/01/2024 | 9,181.00 | 9,356.00 | 54.49 | Buy | No |
LUDWIG EDWARD J | 05/01/2024 | 1,000.00 | 21,630.00 | 53.88 | Buy | No |
COWHEY THOMAS F. | 03/31/2024 | 1,719.00 | 35,642.00 | 79.56 | Sell | No |
Chaguturu Sreekanth K | 03/31/2024 | 825.00 | 11,211.98 | 79.56 | Sell | No |
Chaguturu Sreekanth K | 03/31/2024 | 1,473.00 | 12,036.98 | 79.56 | Sell | No |
Havanec Laurie P. | 03/31/2024 | 7,630.00 | 37,553.00 | 79.56 | Sell | No |
Shah Prem S | 03/31/2024 | 5,239.00 | 42,034.46 | 79.56 | Sell | No |
Shah Prem S | 03/31/2024 | 2,653.00 | 47,273.46 | 79.56 | Sell | No |
Kane Brian A | 03/31/2024 | 12,569.00 | 12,569.00 | n/a | Buy | No |
COWHEY THOMAS F. | 03/31/2024 | 15,082.00 | 47,995.00 | n/a | Buy | No |
Chaguturu Sreekanth K | 03/31/2024 | 6,913.00 | 23,666.00 | 79.56 | Buy | No |
Havanec Laurie P. | 03/31/2024 | 9,426.00 | 9,426.00 | 79.56 | Buy | No |
Joyner J. David | 03/31/2024 | 28,280.00 | 44,241.00 | n/a | Buy | No |
Khichi Samrat S. | 03/31/2024 | 12,569.00 | 44,490.00 | n/a | Buy | No |
Shah Prem S | 03/31/2024 | 15,082.00 | 37,057.00 | n/a | Buy | No |
Shah Prem S | 02/25/2024 | 261.00 | 43,185.46 | 76.43 | Sell | No |
Havanec Laurie P. | 02/25/2024 | 6,698.00 | 45,183.00 | 76.43 | Sell | No |
Clark James David | 02/11/2024 | 2,452.00 | 7,150.00 | n/a | Buy | No |
Lynch Karen S | 02/11/2024 | 136,640.00 | 136,640.00 | n/a | Buy | No |
Havanec Laurie P. | 02/11/2024 | 16,817.00 | 37,203.00 | n/a | Buy | No |
Shah Prem S | 02/11/2024 | 13,313.00 | 69,237.76 | n/a | Buy | No |
Chaguturu Sreekanth K | 02/11/2024 | 1,926.00 | 8,645.19 | n/a | Buy | No |
CVS Health Dividend Calendar
Date | Name | Dividend | *yield | Currency |
---|---|---|---|---|
2023 | CVS Health Corp | 2.48 | 3.14 | USD |
2022 | CVS Health Corp | 2.26 | 2.42 | USD |
2021 | CVS Health Corp | 2.05 | 1.99 | USD |
2020 | CVS Health Corp | 2.00 | 2.93 | USD |
2019 | CVS Health Corp | 2.00 | 2.69 | USD |
2018 | CVS Health Corp | 2.00 | 3.05 | USD |
2017 | CVS Health Corp | 2.00 | 2.76 | USD |
2016 | CVS Health Corp | 1.78 | 2.25 | USD |
2015 | CVS Health Corp | 1.48 | 1.51 | USD |
2014 | CVS Health Corp | 1.18 | 1.22 | USD |
2013 | CVS Health Corp | 0.95 | 1.33 | USD |
2012 | CVS Health Corp | 0.71 | 1.47 | USD |
2011 | CVS Health Corp | 0.54 | 1.32 | USD |
2010 | CVS Health Corp | 0.39 | 1.11 | USD |
2009 | CVS Health Corp | 0.32 | 0.98 | USD |
2008 | CVS Health Corp | 0.26 | 0.90 | USD |
2007 | CVS Health Corp | 0.23 | 0.58 | USD |
2006 | CVS Health Corp | 0.16 | 0.52 | USD |
2005 | CVS Health Corp | 0.14 | 0.53 | USD |
2004 | CVS Health Corp | 0.13 | 0.58 | USD |
2003 | CVS Health Corp | 0.12 | 0.66 | USD |
2002 | CVS Health Corp | 0.12 | 0.96 | USD |
2001 | CVS Health Corp | 0.12 | 0.81 | USD |
2000 | CVS Health Corp | 0.12 | 0.40 | USD |
1999 | CVS Health Corp | 0.12 | 0.60 | USD |
*Yield of the Respective Date
CVS Health Corp Calendar
Event | Estimate | Info | Date |
---|---|---|---|
Earnings Report | 1.754 USD | Q2 2024 Earnings Release | 08/07/2024 |
Earnings Report | - | Q3 2024 Earnings Release | 10/30/2024 |
Earnings Report | - | Q4 2024 Earnings Release | 02/05/2025 |
Earnings Report | 1.505 USD | Q1 2025 Earnings Release | 04/30/2025 |
Earnings Report | 2.041 USD | Q2 2025 Earnings Release | 08/06/2025 |
CVS Health Corp Past Events
Event | Actual EPS | Info | Date |
---|---|---|---|
Annual General Meeting | - | Annual General Meeting | 05/16/2024 |
CVS Health Profile
CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P.
Moody’s Daily Credit Risk Score
CVS Health Shareholder
Owner | in % |
---|---|
Freefloat | 99.82 |
The Vanguard Group, Inc. | 9.37 |
Vanguard Group, Inc. (Subfiler) | 8.79 |
State Street Corp. | 4.38 |
Capital Research & Management Co. (World Investors) | 3.49 |
Dodge & Cox | 3.27 |
Vanguard Total Stock Market ETF | 3.16 |
Capital Research & Management Co. (International Investors) | 3.02 |
Vanguard 500 Index Fund | 2.57 |
Washington Mutual Investors Fund | 2.57 |
BlackRock Fund Advisors | 2.41 |
BlackRock Institutional Trust Co. NA | 2.19 |
Dodge & Cox Stock Fund | 2.19 |
Geode Capital Management LLC | 2.02 |
American Funds Income Fund of America | 1.86 |
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.
CVS Health Management
Name | Job |
---|---|
Roger N. Farah | Chairman |
James D. Clark | Chief Accounting Officer, Senior VP & Controller |
David A. Falkowski | Chief Compliance Officer & Executive VP |
Thomas F. Cowhey | Chief Financial Officer & Senior Vice President |
Chandra McMahon | Chief Information Security Officer & Senior VP |
Sreekanth Chaguturu | Chief Medical Officer & Executive Vice President |
Laurie P. Havanec | Chief People Officer & Executive Vice President |
Prem S. Shah | Chief Pharmacy Officer & President-Pharmacy |
Samrat S. Khichi | Chief Policy Officer, General Counsel & EVP |
Amy Bricker | Chief Product Officer-Consumer & Executive VP |
Sheryl A. Burke | Chief Sustainability Officer & Senior VP |
Deborah LeClerc | Coordinator-Real Estate |
Matthew Tamke | Director-OTC Health Solutions |
Larry Webb | Director-Real Estate |
Holly Jensen | Director-Real Estate & Executive Advisor |
Jenice Tom | Director-Real Estate Market Research & Analytics |
David Berman | Director-Real Estate Metro NY |
Tilak Mandadi | EVP, Chief Data, Digital & Technology Officer |
Katerina Guerraz | EVP, Chief Strategy & Enterprise Affairs Officer |
Alec Cunningham | Executive Vice President |
J. David Joyner | Executive Vice President |
Per G. H. Lofberg | Executive Vice President |
Michelle A. Peluso | Executive Vice President & Chief Customer Officer |
J. Scott Kirby | Independent Director |
Nancy-Ann M. DeParle | Independent Director |
Fernando G. Aguirre | Independent Director |
Jean-Pierre Millon | Independent Director |
C. David Brown | Independent Director |
Alecia A. DeCoudreaux | Independent Director |
Jeffrey R. Balser | Independent Director |
Mary Lovelace Schapiro | Independent Director |
Michael F. Mahoney | Independent Director |
Anne M. Finucane | Independent Director |
Karen S. Lynch | President, Chief Executive Officer & Director |
Michael T. Pykosz | President-Health Services |
Todd Galusha | Real Estate Advisor |
Robin Peterson | Real Estate Director |
Bryan Cook | Regional Director-Real Estate |
Stephen LaBonge | Regional Director-Real Estate |
Madi Rajulapalli | Regional Medical Director-Medicare Case Management |
Robert Holtzman | Regional Real Estate Manager |
Shari M. Slate | SVP, Chief Diversity, Equity & Inclusion Officer |
Laurence McGrath | SVP-Business Development & Investor Relations |
Charles Golden | SVP-Construction & Property Administration |
Jason L. Monroe | Sales Manager |
Kristina V. Fink | Secretary, Chief Governance Officer & Senior VP |
Tracey Drake Weber | Senior VP-Digital Products, UX & Operations |
Melissa A. Schulman | Senior Vice President-Government & Public Affairs |
Carol Ann DeNale | Treasurer & Senior Vice President |
Stephen Frumento | VP-Real Estate & Corporate Acquisitions |
Thomas S. Moffatt | Vice President & Senior Legal Counsel |
Danni Gallagher | Vice President-Construction |
Preet H. Michelson | Vice President-Human Resources |
Michael Kurimcak | Vice President-Real Estate |